Introduction: Middle meningeal artery embolization (MMAE) represents an evolving treatment option for the treatment of recurrent chronic subdural hematomas (cSDH). As of the writing of this abstract, there were 18 randomized controlled trials studying MMAE actively recruiting patients. We identified a gap amongst these on-going trials particularly that one third have an upper age limit which ranged between 89-99 years of age (Table 1). We seek to demonstrate our clinical experience performing MMAE in this sometimes excluded age bracket.
Methods: A consecutive series of MMA embolizations performed between 2019 to 2022 were queried from a prospectively maintained endovascular database with an IRB approved process for data collection. Patients between the ages of 85-99 were reviewed for further analysis. Baseline clinical, perioperative radiographic, and efficacy outcomes were studied.
Results: Eleven patients amongst our series of 77 consecutive cases of MMAE fit the inclusion criteria of this study. 36% of our cohort were females (4 patients). The average age in our cohort was 88.8 years (range of 85-91). Average mRS at last follow up was 3 (range between 0-6). Average follow up time was 3.2 months from the index procedure.
Conclusion : MMAE represents an option for cSDH amongst late octo- and nonagenarians with reasonable short term outcomes. Further study will evaluate the role frailty has in overall outcomes in MMAE for cSDH.
